StocksMedium•5 November 2026•
1 min read
Ironwood Pharmaceuticals Raises FY 2026 Guidance Following Strong Q3 Results
Key Facts
1Ironwood Pharmaceuticals raised its full-year 2026 financial guidance driven by LINZESS net sales growth and strong Q3 performance.
Ironwood Pharmaceuticals raised its full-year 2026 financial guidance driven by LINZESS net sales growth and strong Q3 performance. The company stated in a Business Wire release that the upward revision follows robust demand for its gastrointestinal drug.
IRWD closed at $3.77 on November 4, 2026, with the stock trading between a low of $3.58 and a high of $3.80 during that session. The guidance raise is attributed to continued U.S. net sales growth and the execution of strategic priorities, including the advancement of apraglutide.